Scarica l'app Stockscreener
16.26
2.65%
0.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$15.84
Aprire:
$15.96
Volume 24 ore:
1.00M
Relative Volume:
0.93
Capitalizzazione di mercato:
$748.16M
Reddito:
$159.01M
Utile/perdita netta:
$-21.72M
Rapporto P/E:
-31.27
EPS:
-0.52
Flusso di cassa netto:
$-20.63M
1 W Prestazione:
+8.91%
1M Prestazione:
+29.67%
6M Prestazione:
-9.67%
1 anno Prestazione:
+31.66%
Intervallo 1D:
$15.79
$16.45
Intervallo di 1 settimana:
$14.83
$16.45
Portata 52W:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
Nome
Axogen Inc
Settore
Industria
Telefono
(386) 462-6817
Indirizzo
13631 PROGRESS BLVD., ALACHUA, FL
Confronta AXGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
16.26 | 712.73M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | Lake Street | Buy |
| 2024-07-01 | Iniziato | Raymond James | Outperform |
| 2022-11-11 | Ripresa | Jefferies | Buy |
| 2022-05-09 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | Guggenheim | Buy |
| 2020-06-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Iniziato | Canaccord Genuity | Buy |
| 2018-03-02 | Reiterato | Lake Street | Buy |
| 2018-01-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Iniziato | Jefferies | Buy |
| 2017-11-21 | Reiterato | Lake Street | Buy |
| 2017-07-31 | Iniziato | Leerink Partners | Outperform |
| 2017-06-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Iniziato | ROTH Capital | Buy |
| 2016-11-22 | Aggiornamento | Lake Street | Hold → Buy |
| 2016-11-07 | Reiterato | Wedbush | Outperform |
| 2016-11-03 | Downgrade | Lake Street | Buy → Hold |
| 2016-08-04 | Reiterato | Wedbush | Outperform |
| 2014-05-14 | Iniziato | Dawson James | Buy |
| 2013-10-31 | Reiterato | Ladenburg Thalmann | Buy |
Mostra tutto
Axogen Inc Borsa (AXGN) Ultime notizie
Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
How Axogen Inc. stock performs during market volatility - sundaytimes.kr
Can Axogen Inc. grow without external funding2025 Market Overview & Expert-Curated Trade Recommendations - classian.co.kr
Does Axogen Inc. fit your quant trading modelEntry Point & Advanced Technical Signal Analysis - Newser
Tools to assess Axogen Inc.’s risk profileMarket Weekly Review & Expert Curated Trade Ideas - Newser
Short interest data insights for Axogen Inc.Watch List & Fast Entry Momentum Alerts - Newser
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - MSN
Full technical analysis of Axogen Inc. stockWeekly Trade Review & High Win Rate Trade Alerts - Newser
How to read the order book for Axogen Inc.2025 Price Action Summary & Intraday High Probability Setup Alerts - Newser
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - MSN
Will Axogen Inc. outperform its industry peersTrade Risk Assessment & Weekly Breakout Stock Alerts - newsyoung.net
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth By Investing.com - Investing.com Nigeria
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com India
Axogen Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Weekly Recap & Community Shared Stock Ideas - metal.it
Axogen Inc. stock retracement – recovery analysis2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com
Zurcher Kantonalbank Zurich Cantonalbank Invests $146,000 in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Leading vs lagging indicators on Axogen Inc. performanceTrade Alert System with Volume Analysis - Newser
How high can Axogen Inc. stock goSector Rotation Outlook With Historical Summary - Newser
Price momentum metrics for Axogen Inc. explainedFree Real Time Stock Movement Analysis - Newser
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FY2025 EPS Estimates for AxoGen Raised by Cantor Fitzgerald - Defense World
Is now a turning point for Axogen Inc.Market Forecast Summary Over Multi-Year Period - Newser
AxoGen (NASDAQ:AXGN) Upgraded to Buy at Wall Street Zen - Defense World
Can volume confirm reversal in Axogen Inc.Low Drawdown Picks with Weekly Updates - Newser
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - NewsBreak: Local News & Alerts
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
How to build a custom watchlist for Axogen Inc.Free Stock Selection With High Accuracy - Newser
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Risk adjusted return profile for Axogen Inc. analyzedRisk-Managed Swing Setup and Signal Analysis - Newser
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Jefferies raises AxoGen stock price target to $25 on strong sales growth By Investing.com - Investing.com South Africa
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Axogen Inc Azioni (AXGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axogen Inc Azioni (AXGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levine Alan M | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
36,743 |
| Wendell Amy McBride | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
93,826 |
| Burke William P. Mr. | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
24,484 |
| NEELS GUIDO J | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
86,743 |
| JOHNSON JOHN | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
24,943 |
| TYNDALL JOSEPH A. | Director |
Jun 10 '25 |
Option Exercise |
6.56 |
11,586 |
75,952 |
26,931 |
| TYNDALL JOSEPH A. | Director |
Jun 10 '25 |
Sale |
10.72 |
26,931 |
288,700 |
0 |
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):